ArticlePharmacoEconomics2010
Is there a role for pharmacoeconomics in developing countries?
Article in PharmacoEconomics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pharmacoeconomics and its implication on priority-setting for essential medicines in Tanzania: a systematic review.BMC medical informatics and decision making · 2012Pooled it
- Cost-effectiveness of Procalcitonin (PCT) guidance for antibiotics management of adult sepsis patients in the Egyptian context.BMC health services research · 2024Article
- Pharmacoeconomic Aspects of Diabetes Mellitus: Outcomes and Analysis of Health Benefits Approach.Current diabetes reviews · 2024Review
- Barriers and Facilitators of Pharmacoeconomic Studies: A Review of Evidence from the Middle Eastern Countries.International journal of environmental research and public health · 2022Review
- Forming a medicines pricing policy for low and middle-income countries (LMICs): the case for Pakistan.Journal of pharmaceutical policy and practice · 2022Article
- Pharmacoeconomics in Africa: needs, prospect and challenges.Journal of pharmaceutical policy and practice · 2021Article
- Article
- Key actors' perspectives on cost-effectiveness analysis in Uganda: a cross-sectional survey.BMC health services research · 2014Article
- Comparing cost-effectiveness results for a vaccine across different countries worldwide: what can we learn?Advances in therapy · 2014Article
- Analysis of prices paid by low-income countries - how price sensitive is government demand for medicines?BMC public health · 2014Article
- Southern Med Review to Journal of Pharmaceutical Policy and Practice: broadening the remit!Journal of pharmaceutical policy and practice · 2013Article
- Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries.PharmacoEconomics · 2011Review
- Is there a role for pharmacoeconomics in developing countries?PharmacoEconomics · 2011Article
- Is there a role for pharmacoeconomics in developing countries?PharmacoEconomics · 2011Article
- Is there a role for pharmacoeconomics in developing countries?PharmacoEconomics · 2011Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
21080732What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.